Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757586 | 0.85 | MAPKAPK2 (0.43) | MAPKAPK2SRD5A2MAPK1HTTDOT1L | |
| SCHEMBL17025564 | 0.85 | MAPKAPK2 (0.43) | MAPKAPK2SRD5A2MAPK1HTTDOT1L | |
| SCHEMBL5758369 | 0.84 | MAPKAPK2 (0.43) | MAPKAPK2SRD5A2MAPK1HTTDOT1L | |
| SCHEMBL5757564 | 0.84 | LMNA (0.52) | MAPKAPK2SRD5A2MAPK1HTTHPGD | |
| SCHEMBL22113898 | 0.82 | DOT1L (0.41) | MAPKAPK2MAPK1HTTDOT1LNPC1 | |
| SCHEMBL7689552 | 0.82 | TSHR (0.48) | MAPKAPK2MAPK1DOT1LNPC1RAB9A | |
| SCHEMBL6862365 | 0.81 | PIK3CA (0.51) | MAPKAPK2SRD5A2MAPK1HTTNPC1 | |
| SCHEMBL7230935 | 0.81 | MAP4K4 (0.43) | MAPKAPK2DOT1LNR4A2CHEK2 | |
| SCHEMBL15043774 | 0.81 | SLC2A1 (0.53) | MAPKAPK2MAPK1HTTDOT1LNPC1 | |
| SCHEMBL17025609 | 0.77 | DOT1L (0.39) | MAPKAPK2DOT1LNPC1RAB9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129356-B2 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | ANGIBAUD PATRICK R | 2006-06-22 | — | — | US | disclosed |
| EP-1351954-B1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-01 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1347966-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051835-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | MAPKAPK2 1601/4885SRD5A2 451/4885MAPK1 1797/4885 |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | FNTA, FNTB, CYP7A1 | MAPKAPK2 1798/4885SRD5A2 264/4885MAPK1 1808/4885 |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | FNTA, FNTB, RABGGTB | MAPKAPK2 1214/4885SRD5A2 941/4885MAPK1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.